Kolmar BioTech콜마바이오텍
215380 · KOSDAQ · ₩215380 · 콜마바이오텍
₩2,125▼ ₩15 (0.70%)End-of-day · Oct 29, 2026 · End-of-day prices.
Income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | ₩38B | ₩43B | ₩39B | ₩47B | ₩31B |
| Cost of sales | ₩27B | ₩31B | ₩32B | ₩40B | ₩25B |
| Gross profit | ₩10B | ₩13B | ₩6.3B | ₩6.7B | ₩5.9B |
| Operating income | −₩3.9B | ₩1.8B | −₩4.5B | −₩2.5B | −₩3.5B |
| Net income | −₩5.5B | ₩225M | −₩5.1B | −₩1.9B | −₩1.9B |
| Net income to shareholders | −₩5.5B | ₩225M | −₩5.1B | −₩1.9B | −₩1.9B |
Balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Total assets | ₩87B | ₩95B | ₩98B | ₩95B | ₩100B |
| Current assets | ₩17B | ₩20B | ₩20B | ₩14B | ₩25B |
| Cash and equivalents | ₩3.8B | ₩4B | ₩5.4B | ₩3.6B | ₩455M |
| Total liabilities | ₩63B | ₩65B | ₩76B | ₩65B | ₩69B |
| Current liabilities | ₩30B | ₩31B | ₩46B | ₩45B | ₩38B |
| Borrowings | ₩50B | ₩51B | ₩51B | ₩40B | ₩38B |
| Total equity | ₩23B | ₩29B | ₩22B | ₩30B | ₩31B |
| Shareholders' equity | ₩23B | ₩29B | ₩22B | ₩30B | ₩31B |
Cash flow
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Cash from operations | −₩630M | −₩1.1B | −₩3.2B | ₩2.5B | ₩1.7B |
| Capital spending | ₩254M | ₩292M | ₩836M | ₩11B | ₩37B |
| Free cash flow | −₩884M | −₩1.4B | −₩4.1B | −₩8.9B | −₩35B |
Consolidated where available. Amounts in won.
Also known as: Kolmar BioTech / 콜마바이오텍 / 215380 / KRX:215380
Source: KRX statistical information